Dr. Kim R50 Research Specialist Clinician 2022

摘要 金博士是密歇根大学罗杰尔癌症临床试验项目的一位积极而重要的领导者 中心，其广泛的协作工作从制度上支持了NCI临床试验基础设施 以及全国范围内。她对NCI赞助的临床试验的使命和实施的主要贡献包括：1) 癌症中心神经肿瘤学临床研究小组的机构领导和机构方案 审查委员会；2)担任NCI资助的现场首席调查员和中心研究团队成员 临床试验；3)作为NIH/NCI脑转移兴趣小组联合主席和积极参与的国家领导 NRG和联盟脑瘤委员会成员；4)在实施实践方面的国家领导- 作为NCCN指南中枢神经系统癌症委员会的成员，NCI资助的临床试验的变化结果 以及她所在专业主要期刊的高级副主编。金博士是一位活跃的调查员，他 为介入治疗和非治疗贡献了165名患者登记(支持性和 观察性)试验，自2015年以来，一直担任5项研究人员发起的研究的首席调查员 这是她开发和执行的。最近完成的一项试验现在正在开发中，作为一个多站点 通过NRG脑瘤委员会进行研究。她帮助领导了机构和国家的努力， 扩大对代表性不足的人口和疾病人群的试验资格。通过支持 研究专家奖，金博士建议推进机构临床研究任务，并 建立她的研究和对NCI资助的临床试验的国家领导贡献。直面癌症 该中心的目标是增加干预性试验的总体收益，并增加 少数族裔和女性，金博士提议在整个癌症中心启动一项筛查计划，以 确定并招募符合试验条件的患者参加中枢神经系统转移相关试验(NCI资助的试验 次优应计项目)。从更广泛的肿瘤学中扩大对更多样化的患者群体的覆盖 社区，她建议与密歇根大学附属社区网站合作开发 简化多站点协作流程，推出密歇根大学网络虚拟肿瘤委员会 讨论案件和审判方案，分发时事通讯和举办继续医学教育活动，以提高认识和 参与NCI资助和研究人员发起的试验。她将最终确定并担任校长一职 研究人员通过NRG肿瘤学研究成像的II/III期试验的初始阶段 胶质母细胞瘤患者个体化放射治疗的生物标记物。她将促进新的机构间 作为NIH/NCI脑转移兴趣小组的联合主席，开展合作并发起研究倡议， 并将进一步推动她在支持NCI资助的临床研究方面的参与和国家领导。

Abstract Dr. Kim is an active and vital leader in the clinical trials program at The University of Michigan Rogel Cancer Center whose extensive, collaborative work has supported the NCI clinical trials infrastructure institutionally and nationally. Her key contributions to the mission and conduct of NCI-sponsored clinical trials include: 1) Institutional leadership of the Cancer Center Neuro-Oncology clinical research group and institutional Protocol Review Committee; 2) Serving as site Principal Investigator and central study team member for NCI-funded clinical trials; 3) National leadership as Co-Chair of the NIH/NCI Brain Metastases Interest Group and active member of NRG and Alliance Brain Tumor Committees; 4) National leadership in implementing practice- changing findings from NCI-funded clinical trials as member of the NCCN Guidelines CNS Cancers Committee and Senior Associate Editor of her specialty’s primary journal. Dr. Kim is an active investigator who has contributed 165 patient enrollments to interventional treatment and non-treatment (supportive and observational) trials since 2015, and has served as Principal Investigator of 5 investigator-initiated studies which she has developed and conducted. A recently completed trial is now in development as a multi-site study through the NRG Brain Tumor Committee. She has helped lead institutional and national efforts to broaden trial eligibility for underrepresented demographic and disease populations. Through the support of the Research Specialist Award, Dr. Kim proposes to advance the institutional clinical research mission, and to establish her research and national leadership contribution to NCI funded clinical trials. To address the Cancer Center’s objectives to increase accrual to interventional trials overall, and to increase institutional accrual of minorities and women, Dr. Kim proposes to launch a screening program across the entire Cancer Center to identify and enroll trial-eligible patients for CNS metastases-related trials (NCI-funded trials which have had suboptimal accrual). To expand the catchment of a more diverse patient population from the broader oncology community, she proposes to partner with University of Michigan affiliated community sites to develop streamlined processes for multi-site collaboration, launch a University of Michigan Network virtual tumor board to discuss cases and trial options, distribute newsletters and conduct CME events to increase awareness and participation in NCI-funded and investigator-initiated trials. She will finalize and conduct as Principal Investigator the initial phase of a developing Phase II/III Trial through NRG Oncology investigating an imaging biomarker to personalize radiotherapy in patients with glioblastoma. She will facilitate new inter-institutional collaborations and launch research initiatives as Co-Chair of the NIH/NCI Brain Metastases Interest Group, and will further advance in her participation and national leadership in support of NCI-funded clinical research.